We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
Cap. Flow
-$105M
Cap. Flow %
-10.94%
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.8M
2
SGMT icon
Sagimet Biosciences
SGMT
+$19.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$19.1M
4
CELC icon
Celcuity
CELC
+$16.5M
5
ORKA
Oruka Therapeutics
ORKA
+$13.5M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$57.9M
2
NUVL
Nuvalent
NUVL
+$36.4M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$23.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$18.5M
5
KOD icon
Kodiak Sciences
KOD
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Miscellaneous 6.61%
3 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.3B
$55M 5.72%
206,234
+81,576
+65% +$19.1M
CELC icon
2
Celcuity
CELC
$4.33B
$52.4M 5.45%
500,996
+143,093
+40% +$16.5M
COGT icon
3
Cogent Biosciences
COGT
$6.02B
$49.6M 5.15%
1,280,707
-33,482
-3% -$1.17M
URGN icon
4
UroGen Pharma
URGN
$2.13B
$47.9M 4.98%
1,301,979
-201,066
-13% -$5.45M
IMNM icon
5
Immunome
IMNM
$3.13B
$42.7M 4.44%
2,017,009
+166,731
+9% +$3.57M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.92B
$38M 3.95%
390,000
-264,746
-40% -$23.1M
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.38B
$34.6M 3.59%
311,461
+5,461
+2% +$494K
ORKA
8
Oruka Therapeutics
ORKA
$6.03B
$33.6M 3.49%
352,802
+201,894
+134% +$13.5M
GLUE icon
9
Monte Rosa Therapeutics
GLUE
$1.14B
$26.8M 2.79%
1,108,295
-893,745
-45% -$16.9M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.74B
$26.5M 2.76%
1,214,390
+325,403
+37% +$6.77M
ELVN icon
11
Enliven Therapeutics
ELVN
$4.24B
$24.8M 2.58%
+489,382
New +$20.8M
IMVT icon
12
Immunovant
IMVT
$8.51B
$23.9M 2.48%
619,096
+204,860
+49% +$6.24M
ERAS icon
13
Erasca
ERAS
$6.31B
$23.1M 2.4%
1,263,026
-588,786
-32% -$8.42M
SGMT icon
14
Sagimet Biosciences
SGMT
$656M
$22.6M 2.35%
+2,927,698
New +$19.9M
ABVX
15
Abivax
ABVX
$9.89B
$22.6M 2.35%
169,593
-132,937
-44% -$15M
PRAX icon
16
Praxis Precision Medicines
PRAX
$9.63B
$22M 2.29%
65,679
-5,873
-8% -$1.86M
KOD icon
17
Kodiak Sciences
KOD
$2.37B
$21.3M 2.21%
546,256
-445,674
-45% -$17.3M
ARKG icon
18
PUT
ARK Genomic Revolution ETF
ARKG
$1.88B
$21M 2.19%
+500,000
New +$15.9M
DFTX
19
Definium Therapeutics
DFTX
$5.51B
$18.8M 1.96%
+400,000
New +$9.88M
VCYT icon
20
Veracyte
VCYT
$3.48B
$18.7M 1.94%
318,001
+138,301
+77% +$5.8M
SNDX icon
21
CALL
Syndax Pharmaceuticals
SNDX
$1.74B
$15.2M 1.58%
693,600
+373,600
+117% +$7.77M
GH icon
22
Guardant Health
GH
$21.7B
$15M 1.56%
99,826
+1,312
+1% +$143K
CCCC icon
23
C4 Therapeutics
CCCC
$474M
$14.2M 1.47%
3,032,060
+1,120,275
+59% +$3.83M
ZBIO
24
Zenas BioPharma
ZBIO
$2.04B
$12.9M 1.34%
509,789
-626,146
-55% -$12.4M
TRVI icon
25
Trevi Therapeutics
TRVI
$2.39B
$12.6M 1.31%
678,095
+166,968
+33% +$2.43M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.

  • Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
  • Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
  • Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
  • Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
  • Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
  • Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
  • Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.